Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAXI for Dynamic Forehead Lines
NCT03786770Phase 2Completed
- Sponsor
- Revance Therapeutics
- Start
- Jan 2019
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 2 trial of daxibotulinumtoxinA in glabellar lines, sponsored by Revance Therapeutics. Started Jan 2019; status: completed.
02
Drugs
daxibotulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT03786770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03786770.